Buy & Sell Citius Pharmaceuticals Inc (CTXR) – Citius Pharmaceuticals Inc Price Today
Aura AI Summary
CTXR trades at $0.86, up 1.78% today, with strong analyst support (83% buy ratings) despite recent earnings misses. The company reported its first revenue of $3.9M from LYMPHIR launch in December 2025, though profitability remains challenged with a -909.9% net margin. Recent positive clinical data and international expansion signal growth potential.
Outlook hinges on LYMPHIR commercialization success; upside exists if revenue accelerates, but high cash burn and execution risks warrant caution. The stock offers speculative growth potential with significant binary outcomes based on drug adoption and clinical progress.
Key Stats
- $19.16MMarket Cap
- HealthSector
- -29.17%3M Drawdown
- $13.27MEnterprise Value
- -Dividend Yield
- 53% Buy | 47% SellTrading Activity
- 0 daysTypical Hold Time
52W Low: $0.67
23 Feb 2026
52W High: $2.21
03 Jul 2025
Citius Pharmaceuticals Inc (CTXR) is currently valued at a market capitalization of $19.16M, with an enterprise value of $13.27M. Over the past 52 weeks, Citius Pharmaceuticals Inc has traded between a low of $0.67 and a high of $2.21, highlighting its annual price range. Over the past three months, Citius Pharmaceuticals Inc has recorded a drawdown of -29.17%, reflecting recent price volatility. On average, investors hold Citius Pharmaceuticals Inc for approximately 0 days, indicating typical investor behavior on the platform.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Technical Indicators
|
|
|
Overall Summary
Bearish (13)Neutral (5)Bullish (7)
News
People also bought
US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions